托珠单抗能否用于家族性地中海热?一项系统综述
该系统综述遵循PRISMA指南,从237篇文章中纳入14篇(2项双盲随机对照试验、2项回顾性研究、10例病例报告),评估托珠单抗治疗家族性地中海热的疗效与安全性。双盲随机对照试验结果不一,回顾性研究提示托珠单抗可能对已确诊肾AA淀粉样变患者有益,安全性方面无特定不良事件,但缺乏妊娠、哺乳期及儿童患者数据。
要点
- 双盲随机对照试验在无AA淀粉样变的家族性地中海热患者中结果不一。
- 回顾性研究提示托珠单抗可能对已确诊肾AA淀粉样变患者有益。
- 托珠单抗安全性良好,但缺乏妊娠、哺乳期及儿童患者数据。
核心结论
- IL-1β抑制剂仍是秋水仙碱抵抗或不耐受的家族性地中海热患者的首选。
- 托珠单抗可能对部分已确诊AA淀粉样变且对秋水仙碱和IL-1抑制剂抵抗的家族性地中海热患者有价值。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索到237篇关于托珠单抗用于家族性地中海热的文章。
- 最终纳入14篇文章:2项双盲随机对照试验、2项回顾性研究和10例病例报告。
主要发现
- 多中心双盲随机对照试验在无AA淀粉样变的家族性地中海热患者中报告了混合结果。
- 回顾性研究提示托珠单抗可能使已确诊肾AA淀粉样变的家族性地中海热患者获益,可能阻止疾病进展并更有效地控制发作。
- 托珠单抗显示安全性良好,无特定不良事件,但缺乏妊娠或哺乳期使用数据。
- 无托珠单抗用于儿童家族性地中海热患者的数据。
临床怎么用
- IL-1β抑制剂仍是秋水仙碱抵抗或不耐受的家族性地中海热患者的首选。
- 托珠单抗可能对部分已确诊AA淀粉样变且对秋水仙碱和IL-1抑制剂抵抗的家族性地中海热患者有价值。
局限性
- 双盲随机对照试验因现有研究的遗传/分类异质性、可能的家族性地中海热误诊患者和研究设计而报告混合结果。
- 缺乏托珠单抗在妊娠或哺乳期使用的数据。
- 无托珠单抗用于儿童家族性地中海热患者的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease characterized by recurrent fever and serosal inflammation. Although colchicine is the primary treatment, around 10% of FMF patients do not respond to it, necessitating alternative therapies. Biologic treatments, such as IL-1β, TNF-α and IL-6 inhibitors, have been considered. However, the accessibility and cost of IL-1β inhibitors may limit their use in certain regions. Tocilizumab (TCZ), an IL-6 receptor inhibitor, offers an alternative, but its efficacy in FMF is not well-documented. OBJECTIVE: To evaluate the efficacy and safety of TCZ in the treatment of FMF. METHODS: Following PRISMA guidelines, we identified 237 articles on the use of TCZ in FMF. RESULTS: After selection, 14 articles were included: two double-blind RCTs, two retrospective studies and 10 case reports. Multicentre double-blind RCTs reported mixed results in FMF patients without AA amyloidosis due to genetic/classification heterogeneity of the available studies, possible misdiagnosed FMF patients and study design. Retrospective studies suggest that TCZ may benefit FMF patients with established renal AA amyloidosis, potentially preventing progression and managing flares more effectively. TCZ showed a safe profile with no specific adverse events, but data on its use during pregnancy or breastfeeding are lacking. There was no available data on the use of TCZ in paediatric FMF. CONCLUSION: This review summarizes the current state of research, safety and efficacy of TCZ in FMF. While IL1β inhibitors remain the first choice for colchicine-resistant or intolerant FMF patients, TCZ might be of interest in some selected FMF patients with established AA amyloidosis and resistance to colchicine and interleukin 1 inhibitors.
引用
- Mertz P, Hentgen V, Georgin-Lavialle S, et al. Could tocilizumab be used in familial Mediterranean fever? A systematic review. Rheumatology (Oxford). 2025. PMID: 38950176. doi:10.1093/rheumatology/keae338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。